Dr. MA focuses on combining HPC and AI to drive new drug development. He has exceptional accomplishments in advancing computer-aided drug design, in elucidating the structures and interactions of biological macromolecules, and in understanding protein–protein interactions and their functions. He proposed the conformational selection theory, which is instrumental in deciphering how drug molecules identify and bind to their targets. Dr. MA published more than 200 research papers that were cited over 10,000 times with an h-index of 63. His research results were widely cited and used for studies involving the characterization of protein dynamical properties, enzyme catalysis, protein-protein interactions, drug design, and neurodegenerative diseases.

1991-1995: Studied at the Center for Computational Quantum Chemistry at the University of Georgia, USA and received a doctoral degree.

1995-1998: Postdoc researcher at the Computational Center for Molecular Structure and Design (founded by N.L. Allinger), the University of Georgia, USA.

1998: Joined the National Cancer Institute, USA as a researcher in computational biology.

2020-present: Tenured professor at the School of Pharmacy, Shanghai Jiao Tong University, China.

Dr. KANG received her PhD in Biomedical Engineering from the University of Southern California in 2017. She focuses on the development of mathematical models and functional biomarkers for diseases such as neurodegenerative disorders, type-2 diabetes, and hypertension. She has years of research and product development experience in machine learning and deep learning. Starting from 2020, she turned to focus on AI-assisted protein design, using deep learning to predict antibody affinity based on sequence data. Her method was validated by several projects, including the development of broadly neutralizing antibodies against COVID-19 and the affinity maturation of antibodies against multiple targets. She used to serve as a senior research scientist for AI and head of AI-assisted protein design.。

Dr. TANG received his PhD in Computational Physics from New York University (NYU), USA in 2018, with research interests in high-performance computing, large-scale numerical simulations, data analysis, etc. He has years of experience in scientific computing, data analysis, and data mining. After returning to China in 2020, he has been focusing on studying the application of AI algorithms for macromolecular proteins. As an AI engineer, he has successfully developed algorithms for predicting and designing protein structures.

Dr. Baigang BAI received his PhD in Pharmacy from Shanghai Jiao Tong University in 2024. His research focused on the dual allosteric effect mechanisms of antibody-antigen complexes and allosteric signal transduction. His current research focuses on the integration of biological macromolecule simulation and artificial intelligence algorithms, including molecular dynamics simulations of proteins, antibodies, and nucleic acids, as well as the development of algorithms that combine these simulations with AI.

Dr. LUO is Managing Director of Strategic Investment at Fapon Group, responsible for the group’s investing activities including external investment and the post-investment management and empowerment of companies invested in. He is interested in technology-driven healthcare projects, and is very knowledgeable about the AI-assisted drug development, AI-assisted protein design, and synthetic biology as well as the key players in those fields. Leveraging his industry and business experience, he helps Fapon Digiwiser design investment strategies, prospect for clients, and explore new business models.

2003-2008: Studied at the University of Rochester, USA and received a PhD in Genetics.

2008-2014: Postdoc researcher at Massachusetts General Hospital, Harvard Medical School, USA.

2014-2017: Joined Illumina, developing the next-generation sequencing (NGS) products for cancer diagnosis.

2018-2019: Joined IBM, commercializing IBM Watson Health's products in China.

2019-2023: Joined China Renaissance, doing fund-raising for healthcare startups.

2023-present: Managing Director of Strategic Investment at Fapon Group.